Studies: Pharmaceutical:

Fenretinide Lym-X-Sorb® in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma:

This phase I trial is studying the side effects and best dose of fenretinide Lym-X-Sorb® in treating patients with recurrent or resistant solid tumors or lymphoma. NCT00589381

Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas # 08-C-0030:

A Phase I Study of Fenretinide (4-HPR, NSC 374551) formulated in Lym-X-Sorb® (LXS) as an oral powder will be evaluated in patient with recurrent or resistant neuroblastoma (NEW APPROACHES TO NEUROBLASTOMA THERAPY (NANT) CONSORTIUM, 7/8/05).

NCI - Maurer/CHLA - Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma NCT00295919 New Approaches to Neuroblastoma:

RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Line by Line web design